NCT01122199 - Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 14, 2010

Primary Completion Date

January 19, 2015

Study Completion Date

January 19, 2015

Conditions

Neoplasm Metastases

Interventions

DRUG

RAD001 + AMG479

Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis